Titre : Phosphotransferases (Phosphate Group Acceptor)

Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Transfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes", "headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Phosphotransferases (Phosphate Group Acceptor)" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phosphotransferases", "url": "https://questionsmedicales.fr/mesh/D010770", "about": { "@type": "MedicalCondition", "name": "Phosphotransferases", "code": { "@type": "MedicalCode", "code": "D010770", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Adenylate kinase", "alternateName": "Adenylate Kinase", "url": "https://questionsmedicales.fr/mesh/D000263", "about": { "@type": "MedicalCondition", "name": "Adenylate kinase", "code": { "@type": "MedicalCode", "code": "D000263", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.025" } } }, { "@type": "MedicalWebPage", "name": "ATP synthetase complexes", "alternateName": "ATP Synthetase Complexes", "url": "https://questionsmedicales.fr/mesh/D025181", "about": { "@type": "MedicalCondition", "name": "ATP synthetase complexes", "code": { "@type": "MedicalCode", "code": "D025181", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.150" } } }, { "@type": "MedicalWebPage", "name": "Guanylate kinase", "alternateName": "Guanylate Kinases", "url": "https://questionsmedicales.fr/mesh/D051528", "about": { "@type": "MedicalCondition", "name": "Guanylate kinase", "code": { "@type": "MedicalCode", "code": "D051528", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.450" } } }, { "@type": "MedicalWebPage", "name": "Nucleoside diphosphate kinase", "alternateName": "Nucleoside-Diphosphate Kinase", "url": "https://questionsmedicales.fr/mesh/D009701", "about": { "@type": "MedicalCondition", "name": "Nucleoside diphosphate kinase", "code": { "@type": "MedicalCode", "code": "D009701", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.550" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "NM23 Nucleoside Diphosphate kinases", "alternateName": "NM23 Nucleoside Diphosphate Kinases", "url": "https://questionsmedicales.fr/mesh/D054778", "about": { "@type": "MedicalCondition", "name": "NM23 Nucleoside Diphosphate kinases", "code": { "@type": "MedicalCode", "code": "D054778", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.550.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Nucleoside phosphate kinase", "alternateName": "Nucleoside-Phosphate Kinase", "url": "https://questionsmedicales.fr/mesh/D009703", "about": { "@type": "MedicalCondition", "name": "Nucleoside phosphate kinase", "code": { "@type": "MedicalCode", "code": "D009703", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.696.650.575" } } } ], "about": { "@type": "MedicalCondition", "name": "Phosphotransferases (Phosphate Group Acceptor)", "alternateName": "Phosphotransferases (Phosphate Group Acceptor)", "code": { "@type": "MedicalCode", "code": "D017856", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jean-Marc Jeckelmann", "url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann", "affiliation": { "@type": "Organization", "name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch." } }, { "@type": "Person", "name": "Zengqi Xie", "url": "https://questionsmedicales.fr/author/Zengqi%20Xie", "affiliation": { "@type": "Organization", "name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China." } }, { "@type": "Person", "name": "Bernhard Erni", "url": "https://questionsmedicales.fr/author/Bernhard%20Erni", "affiliation": { "@type": "Organization", "name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland." } }, { "@type": "Person", "name": "Yulin Zhu", "url": "https://questionsmedicales.fr/author/Yulin%20Zhu", "affiliation": { "@type": "Organization", "name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China." } }, { "@type": "Person", "name": "Feng He", "url": "https://questionsmedicales.fr/author/Feng%20He", "affiliation": { "@type": "Organization", "name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36599813", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ejh.13925" } }, { "@type": "ScholarlyArticle", "name": "Systematic reviews on platelet transfusions: Is there unnecessary duplication of effort? A scoping review.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36454598", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/vox.13387" } }, { "@type": "ScholarlyArticle", "name": "The safety of ABO minor incompatible platelets transfusions using a rapid infuser.", "datePublished": "2024-02-01", "url": "https://questionsmedicales.fr/article/38299721", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/trf.17739" } }, { "@type": "ScholarlyArticle", "name": "Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36758527", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529542" } }, { "@type": "ScholarlyArticle", "name": "Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit.", "datePublished": "2022-11-12", "url": "https://questionsmedicales.fr/article/36369934", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/trf.17184" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Transferases", "item": "https://questionsmedicales.fr/mesh/D014166" }, { "@type": "ListItem", "position": 5, "name": "Phosphotransferases", "item": "https://questionsmedicales.fr/mesh/D010770" }, { "@type": "ListItem", "position": 6, "name": "Phosphotransferases (Phosphate Group Acceptor)", "item": "https://questionsmedicales.fr/mesh/D017856" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)", "description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?", "url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Platelet+Transfusion&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en phosphotransférases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases." } }, { "@type": "Question", "name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en phosphotransférases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon le type d'enzyme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils à la naissance ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux enfants ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance." } }, { "@type": "Question", "name": "Peut-on prévenir les déficiences en phosphotransférases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Les tests de dépistage néonatal sont-ils utiles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques préventives ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des recommandations diététiques peuvent être établies pour les familles à risque." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider à prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux en cours ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions." } }, { "@type": "Question", "name": "Comment la gestion diététique aide-t-elle ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces déficiences ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer." } }, { "@type": "Question", "name": "Les troubles cardiaques sont-ils une complication possible ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies métaboliques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour ces déficiences ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque." } }, { "@type": "Question", "name": "L'alimentation peut-elle influencer le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver la condition ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques." } } ] } ] }

Sources (7143 au total)

Systematic reviews on platelet transfusions: Is there unnecessary duplication of effort? A scoping review.

Platelet transfusions are used across multiple patient populations to prevent and correct bleeding. This scoping review aimed to map the currently available systematic reviews (SRs) and evidence-based... A systematic literature search was conducted in seven databases for SRs on effectiveness (including dose and timing, transfusion trigger and ratio to other blood products), production modalities and d... We identified 110 SRs. The majority focused on clinical effectiveness, including prophylactic or therapeutic transfusions compared to no platelet transfusion (34 SRs), prophylactic compared to therape... An interactive evidence map of SRs and evidence-based guidelines in the field of platelet transfusion has been developed and identified multiple reviews. This work serves as a tool for researchers loo...

The safety of ABO minor incompatible platelets transfusions using a rapid infuser.

Administering platelets through a rapid infuser is proven to be safe. However, the clinical significance of infusing ABO-incompatible platelets with red blood cells (RBCs) in a rapid infuser remains u... Seven in vitro studies were performed including five cases (type A RBCs and type O platelets) and two controls (type A RBCs and platelets). Anti-A titers were measured in platelet units. An RBC unit a... The post-mix DAT was positive for IgG in all test samples (5/5), and weakly positive for complement in 3/5. The changes in free Hb in test cases between measured and calculated post-mix spanned -2.2 t... Our study suggested that mixing ABO-incompatible platelets with RBCs in a rapid infuser does not induce in vitro hemolysis. These findings support the use of rapid infusers regardless of platelet comp...

Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.

The aims of this study were to observe the therapeutic effect of platelet (PLT) transfusion and to analyze influencing factors for the sake of providing useful clues for improving the efficacy of PLT ... Included in this study were patients who received PLT transfusion in the affiliated hospital of Nantong University. Patients' sex, age, height, weight, PLT transfusion status, and 20-24-h PLT count be... A total of 364 patients received 1,060 PLT transfusions, including 728 successful transfusions and 332 unsuccessful transfusions. When the patients were grouped according to different etiologies, sign... To reduce PTR, multiple factors should be considered comprehensively when PLT transfusion therapy is to be implemented in clinical practice. PLT antibody is the main immune factor causing PTR....

Platelet transfusion practice pattern before and after implementation of a local restrictive transfusion protocol in a neonatal intensive care unit.

Following the results of the PlaNeT-2 randomized controlled trial showing decreased morbidity and mortality in neonates transfused at a threshold of 25 versus 50 × 10... Prospective observational cohort chart-review study comparing all neonates consecutively admitted to the NICU during two 5-months periods: 2013 (before; N = 401) versus 2021 (after; N = 402). Possible... Mean (± standard deviation) gestational age and birth weight were 34.9 ± 4.2 weeks and 2.5 ± 1.0 kg, respectively. In 2021, 5.0% were platelet-transfused versus 9.2% in 2013 (p = .027). Platelet trans... Restrictive local transfusion thresholds in a NICU decreased the proportion of platelet-transfused neonates by 46% and reduced donor exposure in transfused patients....

Two-year outcomes following a randomised platelet transfusion trial in preterm infants.

Assess mortality and neurodevelopmental outcomes at 2 years of corrected age in children who participated in the PlaNeT-2/MATISSE (Platelets for Neonatal Transfusion - 2/Management of Thrombocytopenia... Randomised clinical trial, enrolling from June 2011 to August 2017. Follow-up was complete by January 2020. Caregivers were not blinded; however, outcome assessors were blinded to treatment group.... 43 level II/III/IV neonatal intensive care units (NICUs) across UK, Netherlands and Ireland.... 660 infants born at less than 34 weeks' gestation with platelet counts less than 50×10... Infants were randomised to undergo a platelet transfusion at platelet count thresholds of 50×10... Our prespecified long-term follow-up outcome was a composite of death or neurodevelopmental impairment (developmental delay, cerebral palsy, seizure disorder, profound hearing or vision loss) at 2 yea... Follow-up data were available for 601 of 653 (92%) eligible participants. Of the 296 infants assigned to the higher threshold group, 147 (50%) died or survived with neurodevelopmental impairment, as c... Infants randomised to a higher platelet transfusion threshold of 50×10... ISRCTN87736839....

Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury.

Transfusion-related acute lung injury (TRALI) is a severe complication of blood transfusion that is thought of as a two-hit event: first the underlying patient condition (e.g., sepsis), and then the t... In a randomized controlled trial, 18 healthy male volunteers received a first hit of experimental endotoxemia (2 ng/kg lipopolysaccharide), and a second hit of fresh (2-day old) or aged (7-day old) au... All subjects reacted adequately to lipopolysaccharide infusion and satisfied SIRS criteria (increased pulse [>90/min] and temperature [>38°C]). There were no differences between the saline, fresh, and... In a human endotoxemia model of autologous platelet transfusion, with an adequate first hit and platelet storage lesion, transfusion of 7-day-old PC does not increase pulmonary inflammation compared w...

A randomized cross-over study of cryopreserved platelets in prophylactic transfusions of thrombocytopenic patients.

The short shelf-life of liquid-stored platelets (LP) at 20-24°C poses shortage and wastage challenges. Cryopreserved platelets have significantly extended shelf-life, and were safe and efficacious for... We performed a phase 1b/2a randomized cross-over study comparing the safety and efficacy of cryopreserved buffy coat-derived pooled platelets (CP) to LP in the prophylactic transfusions of thrombocyto... A total of 18 adults were randomly assigned 1:1 to CP and LP for their first thrombocytopenic period (TP) of up to 28-days. A total of 14 crossed over to the other platelet-arm for the second TP. Over... During shortages, CP may supplement LP in prophylactic transfusions of thrombocytopenic patients....